| Patient baseline characteristic . | Talazoparib (N = 61) . |
|---|---|
| Age (years) | |
| Median (min-max) | 42 (26-75) |
| Sex, n (%) | |
| Female | 61 (100.0) |
| Menopausal status, n (%) | |
| Premenopausal | 36 (59.0) |
| Postmenopausal | 25 (41.0) |
| Race, n (%) | |
| White | 47 (77.0) |
| Black or African American | 7 (11.5) |
| Asian | 3 (4.9) |
| Not reported | 4 (6.6) |
| Ethnicity, n (%) | |
| African American | 7 (11.5) |
| Ashkenazi Jewish | 1 (1.6) |
| Chinese | 1 (1.6) |
| Othera | 52 (85.2) |
| Hispanic or Latino | 3 (4.9) |
| Not Hispanic or Latino | 42 (68.9) |
| Not reported | 7 (11.5) |
| Breast cancer | |
| Duration since onset (weeks) | |
| Mean (min-max) | 4.54 (0.4-21.1) |
| Adenocarcinoma, n (%) | 60 (98.4) |
| Squamous carcinoma with spindle cell, n (%) | 1 (1.6) |
| TNBC, n (%) | 61 (100.0) |
| BRCA1, n (%) | 48 (78.7) |
| BRCA2, n (%) | 13 (21.3) |
| Staging, n (%) | |
| Stage I | 20 (32.8) |
| Stage II | 27 (44.3) |
| Stage III | 14 (23.0) |
| Patient baseline characteristic . | Talazoparib (N = 61) . |
|---|---|
| Age (years) | |
| Median (min-max) | 42 (26-75) |
| Sex, n (%) | |
| Female | 61 (100.0) |
| Menopausal status, n (%) | |
| Premenopausal | 36 (59.0) |
| Postmenopausal | 25 (41.0) |
| Race, n (%) | |
| White | 47 (77.0) |
| Black or African American | 7 (11.5) |
| Asian | 3 (4.9) |
| Not reported | 4 (6.6) |
| Ethnicity, n (%) | |
| African American | 7 (11.5) |
| Ashkenazi Jewish | 1 (1.6) |
| Chinese | 1 (1.6) |
| Othera | 52 (85.2) |
| Hispanic or Latino | 3 (4.9) |
| Not Hispanic or Latino | 42 (68.9) |
| Not reported | 7 (11.5) |
| Breast cancer | |
| Duration since onset (weeks) | |
| Mean (min-max) | 4.54 (0.4-21.1) |
| Adenocarcinoma, n (%) | 60 (98.4) |
| Squamous carcinoma with spindle cell, n (%) | 1 (1.6) |
| TNBC, n (%) | 61 (100.0) |
| BRCA1, n (%) | 48 (78.7) |
| BRCA2, n (%) | 13 (21.3) |
| Staging, n (%) | |
| Stage I | 20 (32.8) |
| Stage II | 27 (44.3) |
| Stage III | 14 (23.0) |
Abbreviations: BRCA1/2, breast cancer susceptibility genes 1 and 2; ITT, intent-to-treat; max, maximum; min, minimum; TNBC, triple-negative breast cancer.
a“Other” includes 3 patients who were not recorded in the “Other” category (designation left blank) but reported their ethnicity as Hispanic or Latino (n = 1), Not Hispanic or Latino (n = 1) and Not Reported (n = 1)
| Patient baseline characteristic . | Talazoparib (N = 61) . |
|---|---|
| Age (years) | |
| Median (min-max) | 42 (26-75) |
| Sex, n (%) | |
| Female | 61 (100.0) |
| Menopausal status, n (%) | |
| Premenopausal | 36 (59.0) |
| Postmenopausal | 25 (41.0) |
| Race, n (%) | |
| White | 47 (77.0) |
| Black or African American | 7 (11.5) |
| Asian | 3 (4.9) |
| Not reported | 4 (6.6) |
| Ethnicity, n (%) | |
| African American | 7 (11.5) |
| Ashkenazi Jewish | 1 (1.6) |
| Chinese | 1 (1.6) |
| Othera | 52 (85.2) |
| Hispanic or Latino | 3 (4.9) |
| Not Hispanic or Latino | 42 (68.9) |
| Not reported | 7 (11.5) |
| Breast cancer | |
| Duration since onset (weeks) | |
| Mean (min-max) | 4.54 (0.4-21.1) |
| Adenocarcinoma, n (%) | 60 (98.4) |
| Squamous carcinoma with spindle cell, n (%) | 1 (1.6) |
| TNBC, n (%) | 61 (100.0) |
| BRCA1, n (%) | 48 (78.7) |
| BRCA2, n (%) | 13 (21.3) |
| Staging, n (%) | |
| Stage I | 20 (32.8) |
| Stage II | 27 (44.3) |
| Stage III | 14 (23.0) |
| Patient baseline characteristic . | Talazoparib (N = 61) . |
|---|---|
| Age (years) | |
| Median (min-max) | 42 (26-75) |
| Sex, n (%) | |
| Female | 61 (100.0) |
| Menopausal status, n (%) | |
| Premenopausal | 36 (59.0) |
| Postmenopausal | 25 (41.0) |
| Race, n (%) | |
| White | 47 (77.0) |
| Black or African American | 7 (11.5) |
| Asian | 3 (4.9) |
| Not reported | 4 (6.6) |
| Ethnicity, n (%) | |
| African American | 7 (11.5) |
| Ashkenazi Jewish | 1 (1.6) |
| Chinese | 1 (1.6) |
| Othera | 52 (85.2) |
| Hispanic or Latino | 3 (4.9) |
| Not Hispanic or Latino | 42 (68.9) |
| Not reported | 7 (11.5) |
| Breast cancer | |
| Duration since onset (weeks) | |
| Mean (min-max) | 4.54 (0.4-21.1) |
| Adenocarcinoma, n (%) | 60 (98.4) |
| Squamous carcinoma with spindle cell, n (%) | 1 (1.6) |
| TNBC, n (%) | 61 (100.0) |
| BRCA1, n (%) | 48 (78.7) |
| BRCA2, n (%) | 13 (21.3) |
| Staging, n (%) | |
| Stage I | 20 (32.8) |
| Stage II | 27 (44.3) |
| Stage III | 14 (23.0) |
Abbreviations: BRCA1/2, breast cancer susceptibility genes 1 and 2; ITT, intent-to-treat; max, maximum; min, minimum; TNBC, triple-negative breast cancer.
a“Other” includes 3 patients who were not recorded in the “Other” category (designation left blank) but reported their ethnicity as Hispanic or Latino (n = 1), Not Hispanic or Latino (n = 1) and Not Reported (n = 1)
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
